{"id":"haplo-cord-hct","safety":{"commonSideEffects":[{"rate":null,"effect":"Graft-versus-host disease"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Engraftment failure"},{"rate":null,"effect":"Hematologic toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a cellular therapy utilizing haploidentical (half-matched) umbilical cord blood stem cells for transplantation. The product aims to provide hematopoietic reconstitution with reduced graft-versus-host disease risk through the use of cord blood-derived cells, which have immunological properties that may be more tolerant than bone marrow-derived cells.","oneSentence":"Haplo-cord HCT is a hematopoietic stem cell transplantation product derived from haploidentical cord blood designed to reconstitute hematopoietic and immune function.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:42.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies requiring stem cell transplantation"},{"name":"Severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT06381817","phase":"PHASE3","title":"Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-04-01","conditions":"Acute T Cell Lymphoblastic Leukemia, Haploidentical Hematopoietic Stem Cell Transplantation, Cord Blood","enrollment":146},{"nctId":"NCT03719534","phase":"PHASE3","title":"Haplo HCT vs Haplo-cord HCT for Patients With AML","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2017-06-01","conditions":"Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Haplo-cord HCT","genericName":"Haplo-cord HCT","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"Haplo-cord HCT is a hematopoietic stem cell transplantation product derived from haploidentical cord blood designed to reconstitute hematopoietic and immune function. Used for Hematologic malignancies requiring stem cell transplantation, Severe aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}